World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 30 June 2019
Main ID:  EUCTR2004-004512-23-IE
Date of registration: 15/02/2005
Prospective Registration: Yes
Primary sponsor: BioMarin Pharmaceutical Inc.
Public title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Phenoptin in Subjects with Phenylketonuria Who Have Elevated Phenylalanine Levels - NA
Scientific title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Phenoptin in Subjects with Phenylketonuria Who Have Elevated Phenylalanine Levels - NA
Date of first enrolment: 22/05/2005
Target sample size: 100
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-004512-23
Study type:  Interventional clinical trial of medicinal product
Study design: 
Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
 
Phase:  Human pharmacology (Phase I): Therapeutic exploratory (Phase II): Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV):
Countries of recruitment
Germany Ireland Italy United Kingdom
Contacts
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria:
1. 8 years of age and older
2. Received at least 7 out of 8 scheduled doses in Study PKU-001
3. Responsive to Phenoptin in Study PKU-001, defined as a reduction in blood Phe level of =/> 30% compared with baseline
4. Blood Phe level =/> 600 µmol/L at screening
5. Willing and able to provide written informed consent or, in the case of subjects under the age of 18, provide written assent (if required) and written informed consent by a parent or legal guardian, after the nature of the study has been explained
6. Negative urine pregnancy test at screening (females of child-bearing potential)
7. Female subjects of childbearing potential (if sexually active) must be using acceptable birth control measures, as determined by the investigator, and willing to continue to use acceptable birth control measures while participating in the study
8. Willing and able to comply with study procedures
9. Willing to continue current diet unchanged while participating in the study

Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
1. Perceived to be unreliable or unavailable for study participation or, if under the age of 18, have parents or legal guardians who are perceived to be unreliable or unavailable
2. Use of any investigational agent other than Phenoptin within 30 days prior to screening, or requirement for any investigational agent or investigational vaccine prior to completion of all scheduled study assessments
3. Pregnant or breastfeeding, or considering pregnancy
4. ALT >5 times the upper limit of normal (i.e., Grade 3 or higher based on World Health Organization Toxicity Criteria) at screening
5. Concurrent disease or condition that would interfere with study participation or safety (e.g., seizure disorder, oral steroid-dependent asthma or other condition requiring oral or parenteral corticosteroid administration, or insulin-dependent diabetes, or organ transplantation recipient)
6. Serious neuropsychiatric illness (e.g., major depression) not currently under medical management
7. Requirement for concomitant treatment with any drug known to inhibit folate synthesis (e.g., methotrexate)
8. Concurrent use of levodopa
9. Clinical diagnosis of primary BH4 deficiency



Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Phenylketonuria (PKU)
MedDRA version: 6.1 Classification code 10034872
Intervention(s)

Product Name: Phenoptin
Product Code: T1401
Pharmaceutical Form: Tablet
INN or Proposed INN: Sapropterin, sapropterin hydrochloride
CAS Number: 69056-38-8
Concentration unit: mg milligram(s)
Concentration type: not less then
Concentration number: 100-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use

Primary Outcome(s)

Secondary Objective: The secondary objectives are:
1. To evaluate the safety of Phenoptin versus placebo in this subject population.
2. To evaluate the efficacy of Phenoptin versus placebo in this subject population with respect to:
The mean change in weekly blood Phe levels during the 6 weeks of treatment.
The proportion of subjects who have blood Phe levels =/< 600 µmol/L at Week 6.
Main Objective: The primary objective is to evaluate the efficacy of Phenoptin in reducing blood Phe levels in subjects with phenylketonuria.
Primary end point(s): The primary efficacy endpoint is the Phe level at Week 6, which will be compared by testing the difference in mean blood Phe levels in the placebo and Phenoptin treatment groups at Week 6. The Week 6 mean blood Phe levels in each group will be compared using an analysis of covariance model with baseline Phe level and treatment as the only covariates. The model willl utilize a last observation carried forward (LOCF) imputation approach to deal with missing data.
Secondary Outcome(s)
Secondary ID(s)
PKU-003
Source(s) of Monetary Support
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date:
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history